Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089761 | 0.86 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBMETTL3 | |
| SCHEMBL1799337 | 0.86 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBMETTL3 | |
| SCHEMBL22002116 | 0.80 | PRMT5 (0.42) | METTL3PRMT5WDR77 | |
| SCHEMBL22001980 | 0.79 | PRMT5 (0.42) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL18009826 | 0.79 | RAPGEF3 (0.39) | PRMT5WDR77 | |
| SCHEMBL18009824 | 0.79 | RAPGEF3 (0.39) | PRMT5WDR77 | |
| SCHEMBL18026201 | 0.79 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBADK | |
| SCHEMBL14440906 | 0.78 | RAPGEF3 (0.48) | PRMT5WDR77 | |
| SCHEMBL18572574 | 0.77 | METTL3 (0.46) | METTL3METTL14ADKPRMT5WDR77 | |
| SCHEMBL20475706 | 0.76 | PRMT5 (0.48) | PI4KAPI4K2BPI4K2API4KBPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220205026-A1 | Use of Biomarkers in Identifying Cancer Patients That Will Be Responsive to Treatment With a PRMT5 Inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-30 | — | — | US | disclosed |